<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOSEASONIQUE- levonorgestrel/ethinyl estradiol and ethinyl estradiol 
			 </strong><br>Teva Women's Health, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LoSeasonique tablets safely and effectively. See full prescribing information for LoSeasonique.<br>LoSeasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) for oral use<br>Initial U.S. Approval: 1982 </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul>
<li><span class="Bold">Women who are over 35 years old and smoke should not use LoSeasonique. (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</span></li>
<li><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul>
<li><span class="Bold">Women who are over 35 years old and smoke should not use LoSeasonique. (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</span></li>
<li><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LoSeasonique is an estrogen/progestin COC indicated for use by women to prevent pregnancy. (<a href="#i4i_indications_id_9d02b4be-f080-4a2c-a348-141ba55d2628">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Take one tablet daily by mouth at the same time every day for 91 days. (<span class="Underline"><a href="#i4i_dosage_admin_id_8b5574d1-3d47-4526-b1b4-a19013a115e4">2</a></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">LoSeasonique consists of 84 orange tablets containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, and 7 yellow tablets containing 0.01 mg ethinyl estradiol. (<a href="#i4i_dosage_form_strength_id_dbd295c4-bb3f-4e2a-92c2-f2046a298583">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>A high risk of arterial or venous thrombotic diseases (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</li>
<li>Breast cancer or other estrogen- or progestin-sensitive cancer (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span> or liver disease (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</li>
<li>Pregnancy (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Vascular risks: Stop LoSeasonique if a thrombotic event occurs. Stop LoSeasonique at least 4 weeks before and through 2 weeks after major surgery. Start LoSeasonique no earlier than 4 weeks after delivery, in women who are not breastfeeding. (<a href="#i4i_section_id_f2f07b29-694c-494f-baa1-e4f0df88e4b9">5.1</a>)</li>
<li>Liver disease: Discontinue LoSeasonique if <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs. (<a href="#i4i_section_id_34c1c3b7-9730-42e0-ab54-4186bc8484fe">5.3</a>)</li>
<li>High blood pressure: Do not prescribe LoSeasonique for women with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with vascular disease. (<a href="#i4i_section_id_04a1d7c1-16e0-4d40-821e-db74e44a0e85">5.4</a>)</li>
<li>Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking LoSeasonique. Consider an alternate contraceptive method for women with uncontrolled <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. (<a href="#i4i_section_id_1e2ef815-fd18-4fdc-bb69-810556a828e0">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: Evaluate significant change in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and discontinue LoSeasonique if indicated. (<a href="#i4i_section_id_cb685eb2-66a9-4674-b232-724c0b893d41">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine bleeding</span>: Evaluate irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. (<a href="#i4i_section_id_66eb0898-d469-448c-97d5-f540707300e3">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions for COCs are irregular <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. (<a href="#i4i_adverse_effects_id_1f65d159-db27-4337-8ed7-dfe381061a57">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact <span class="Bold">Teva Women’s Health at 1-800-222-0190</span> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs. (<span class="Underline"><a href="#i4i_interactions_id_7311004a-7f40-41e6-8d38-b6ab6a1e686a">7</a></span>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Nursing: Not recommended for nursing mothers; can decrease milk production (<a href="#i4i_nursing_mothers_id_620bb399-fd38-4639-a372-eb22e95c21cc">8.3</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Vascular Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Carcinoma of the Breast and Cervix</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Liver Disease</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 High Blood Pressure</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Carbohydrate and Lipid Metabolic Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Interference with Laboratory Tests</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Monitoring</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Changes in Contraceptive Effectiveness Associated with Co-Administration of Other Products</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Increase in Plasma Levels of Estradiol Associated with Co-Administered Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Changes in Plasma Levels of Co-Administered Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_eb92d147-ea72-4cff-8ade-2bf48deb4dda"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</span></h1>
<p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. <span class="Italics">[See CONTRAINDICATIONS (<a href="#i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf">4</a>).]</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9d02b4be-f080-4a2c-a348-141ba55d2628"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LoSeasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) is indicated for use by women to prevent pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8b5574d1-3d47-4526-b1b4-a19013a115e4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Take one tablet by mouth at the same time every day. The dosage of LoSeasonique  is one orange tablet containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by one yellow ethinyl estradiol tablet for 7 days. To achieve maximum contraceptive effectiveness, LoSeasonique must be taken exactly as directed and at intervals not exceeding 24 hours.</p>
<p>Instruct the patient to begin taking LoSeasonique on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first orange tablet is taken that day. One orange tablet should be taken daily for 84 consecutive days, followed by one yellow tablet for 7 consecutive days. A non-hormonal back-up method of contraception (such as condoms or spermicide) should be used until an orange tablet has been taken daily for 7 consecutive days. A scheduled period should occur during the 7 days that the yellow tablets are taken.</p>
<p>Begin the next and all subsequent 91-day cycles without interruption on the same day of the week (Sunday) on which the patient began her first dose of LoSeasonique, following the same schedule: 84 days taking an orange tablet followed by 7 days taking a yellow tablet. If the patient does not immediately start her next pill pack, she should protect herself from pregnancy by using a non-hormonal back-up method of contraception until she has taken an orange tablet daily for 7 consecutive days.</p>
<p>If unscheduled spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, instruct the patient to continue on the same regimen. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is persistent or prolonged, advise the patient to consult her healthcare provider.</p>
<p>For patient instructions regarding missed pills, <span class="Italics">see PATIENT COUNSELING INFORMATION (<a href="#i4i_section_id_5220d496-3129-43f4-b60e-8df191fd6004">17.2</a>)</span>.</p>
<p>For postpartum women who are not breastfeeding, start LoSeasonique no earlier than four to six weeks postpartum. If the patient starts on LoSeasonique postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken an orange tablet for 7 consecutive days.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_dbd295c4-bb3f-4e2a-92c2-f2046a298583"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">LoSeasonique tablets are available in Extended-Cycle Tablet Dispensers, each containing a 13-week supply of tablets: 84 orange tablets, each containing 0.1 mg of levonorgestrel and 0.02 mg ethinyl estradiol, and 7 yellow tablets each containing 0.01 mg of ethinyl estradiol. The orange tablets are round, film-coated, unscored tablets with a debossed stylized <span class="Bold">b</span> on one side and <span class="Bold">28 </span>on the other side. The yellow tablets are round, film-coated, unscored tablet with a debossed stylized <span class="Bold">b </span>on one side and <span class="Bold">556</span>  on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_8ada34e6-c258-47f1-a940-d6f4400157cf"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Do not prescribe LoSeasonique to women who are known to have the following conditions:</p>
<ul>
<li>A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<ul>
<li>Smoke, if over age 35</li>
<li>Have <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, now or in the past</li>
<li>Have cerebrovascular disease</li>
<li>Have <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span></li>
<li>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, <span class="product-label-link" type="condition" conceptid="4249899" conceptname="Subacute bacterial endocarditis">subacute bacterial endocarditis</span> with valvular disease, or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>)</li>
<li>Have hypercoagulopathies</li>
<li>Have <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span></li>
<li>Have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with vascular disease</li>
<li>Have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> with focal neurological symptoms or have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> if over age 35</li>
</ul>
</li>
<li>Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, benign or malignant, or liver disease</li>
<li>Pregnancy, because there is no reason to use OCs during pregnancy</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_51794ddd-b869-401e-8282-b73e12d949c8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2f07b29-694c-494f-baa1-e4f0df88e4b9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Vascular Events</h2>
<p class="First">Stop COCs if an arterial or deep venous thrombotic event occurs. Although use of COCs increases the risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>, pregnancy increases the risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> as much or more than the use of COCs. The risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> in women using COCs is 3 to 9 per 10,000 woman-years. Use of COCs also increases the risk of arterial thromboses such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>, especially in women with other risk factors for these events.</p>
<p>Use of LoSeasonique provides women with more hormonal exposure on a yearly basis than conventional monthly oral contraceptives containing the same strength synthetic estrogens and progestins (an additional 9 and 13 weeks of exposure to progestin and estrogen, respectively, per year.)</p>
<p>If feasible, stop COCs at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>.</p>
<p>Start COCs no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.</p>
<p>Stop COCs if there is unexplained <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, or retinal vascular lesions. Evaluate for <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span> immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c6401f3-e220-49dd-9c5a-b0261311ed05"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Carcinoma of the Breast and Cervix</h2>
<p class="First">Women who currently have or have had breast cancer should not use COCs because breast cancer may be hormonally sensitive.</p>
<p>There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.</p>
<p>Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings are due to differences in sexual behavior and other factors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34c1c3b7-9730-42e0-ab54-4186bc8484fe"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Liver Disease</h2>
<p class="First">Discontinue COCs if <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops. Steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt; 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.</p>
<p>Oral contraceptive-related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> may occur in women with a history of pregnancy-related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>. Women with a history of COC-related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> may have the condition recur with subsequent COC use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04a1d7c1-16e0-4d40-821e-db74e44a0e85"></a><a name="section-5.4"></a><p></p>
<h2>5.4 High Blood Pressure</h2>
<p class="First">For women with well-controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, monitor blood pressure and stop COCs if blood pressure rises significantly. Women with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with vascular disease should not use COCs.</p>
<p>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use. The incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing concentration of progestin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d868ef5-8e68-4e54-aed9-c68412c9938b"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">Studies suggest a small increased relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among COC users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e2ef815-fd18-4fdc-bb69-810556a828e0"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Carbohydrate and Lipid Metabolic Effects</h2>
<p class="First">Carefully monitor prediabetic and diabetic women who are taking COCs. COCs may decrease glucose tolerance in a dose-related fashion.</p>
<p>Consider alternative contraception for women with uncontrolled <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. A small proportion of women will have adverse lipid changes while on COCs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb685eb2-66a9-4674-b232-724c0b893d41"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">If a woman taking COCs develops new <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that are recurrent, persistent, or severe, evaluate the cause and discontinue COCs if indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66eb0898-d469-448c-97d5-f540707300e3"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities</h2>
<p class="First">Unscheduled (breakthrough) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting sometimes occur in patients on COCs, especially during the first 3 months of use. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> persists, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> irregularities may resolve over time or with a change to a different COC product.</p>
<p>When prescribing LoSeasonique, the convenience of fewer planned menses (4 per year instead of 13 per year) should be weighed against the inconvenience of increased unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting. The clinical trial that evaluated the efficacy of LoSeasonique also assessed unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The participants in this 12-month clinical trial (N=2,185) completed the equivalent of over 20,000 28-day cycles of exposure and were composed primarily of women who had used OCs previously (89%), as opposed to new users (11%). A total of 209 subjects (9.6%) discontinued LoSeasonique, at least in part, due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting.</p>
<p>Scheduled (withdrawal) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting remained fairly constant over time, with an average of 2-3 days of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting per each 91-day cycle. Unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and unscheduled spotting decreased over successive 91-day cycles. <a href="#id_94cae6b2-1a1e-422e-9c41-820731d745a2">Table 1</a> below presents the number of days with unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in treatment cycles 1 and 4. <a href="#id_91c04f3f-a83d-4977-b3c8-3398bbf0e12f">Table 2</a> presents the number of days with unscheduled spotting in treatment cycles 1 and 4.</p>
<a name="id_94cae6b2-1a1e-422e-9c41-820731d745a2"></a><table border="single" width="450.000">
<caption><span>Table 1: Total Number of Days with Unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></caption>
<col width="16.9%">
<col width="15.1%">
<col width="15.1%">
<col width="15.1%">
<col width="15.1%">
<col width="22.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">91-Day Treatment Cycle</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle"><span class="Bold">Days per 84-Day Interval</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Days per 28-Day Interval</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Q1</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Median</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Q3</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Mean</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Mean</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">1st</td>
<td class="Botrule Rrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
<td class="Botrule Rrule" align="center" valign="middle">11</td>
<td class="Botrule Rrule" align="center" valign="middle">7.5</td>
<td class="Botrule" align="center" valign="middle">2.5</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="middle">4th</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">5</td>
<td class="Rrule" align="center" valign="middle">3.5</td>
<td class="Botrule" align="center" valign="middle">1.2</td>
</tr>
</tbody>
</table>
<p> Q1=Quartile 1: 25% of women had this number of days of unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p>Median: 50% of women had ≤ this number of days of unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p>Q3=Quartile 3: 75% of women had ≤ this number of days of unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<a name="id_91c04f3f-a83d-4977-b3c8-3398bbf0e12f"></a><table border="single" width="450.000">
<caption><span>Table 2: Total Number of Days with Unscheduled Spotting</span></caption>
<col width="16.9%">
<col width="15.1%">
<col width="15.1%">
<col width="15.1%">
<col width="15.1%">
<col width="22.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">91-Day Treatment Cycle</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="middle"><span class="Bold">Days per 84-Day Interval</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Days per 28-Day Interval</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Q1</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Median</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Q3</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Mean</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Mean</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">1st</td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
<td class="Botrule Rrule" align="center" valign="middle">10</td>
<td class="Botrule Rrule" align="center" valign="middle">19</td>
<td class="Botrule Rrule" align="center" valign="middle">14.0</td>
<td class="Botrule" align="center" valign="middle">4.7</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="middle">4th</td>
<td class="Rrule" align="center" valign="middle">0</td>
<td class="Rrule" align="center" valign="middle">3</td>
<td class="Rrule" align="center" valign="middle">10</td>
<td class="Rrule" align="center" valign="middle">6.5</td>
<td class="Botrule" align="center" valign="middle">2.2</td>
</tr>
</tbody>
</table>
<p> Q1=Quartile 1: 25% of women had ≤ this number of days of unscheduled spotting</p>
<p>Median: 50% of women had ≤ this number of days of unscheduled spotting</p>
<p>Q3=Quartile 3: 75% of women had ≤ this number of days of unscheduled spotting</p>
<p>Figure 1 shows the percentage of LoSeasonique subjects participating in the primary clinical trial with ≥ 7 days or ≥ 20 days of unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting, or just unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, during each 91-day treatment cycle.</p>
<div class="Figure">
<img alt="Chart: Percent of women taking LoSeasonique who reported unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting (based on daily diaries)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-01.jpg"><p class="MultiMediaCaption">Figure 1. Percent of Women Taking LoSeasonique who Reported Unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and/or Spotting (Based on Daily Diaries)</p>
</div>
<p><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> sometimes occurs in women who are using COCs. Pregnancy should be ruled out in the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. Some women may encounter <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span> after stopping COCs, especially when such a condition was pre-existent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b49704d5-8bbc-4a3a-af38-ee7ac270d280"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Interference with Laboratory Tests</h2>
<p class="First">The use of COCs may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of <span class="product-label-link" type="condition" conceptid="4188578" conceptname="Thyroxine binding globulin">thyroid binding globulin</span> increase with use of COCs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f3f0665-82d2-4815-89ce-da74626b3cbe"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Monitoring</h2>
<p class="First">A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_1f65d159-db27-4337-8ed7-dfe381061a57"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:</p>
<ul>
<li>Serious cardiovascular events and smoking <span class="Italics">[see BOXED WARNING] </span>
</li>
<li>Vascular events<span class="Italics"> [see WARNINGS AND PRECAUTIONS (<a href="#i4i_section_id_f2f07b29-694c-494f-baa1-e4f0df88e4b9">5.1</a>)]</span>
</li>
<li>Liver disease <span class="Italics"> [see WARNINGS AND PRECAUTIONS (<a href="#i4i_section_id_34c1c3b7-9730-42e0-ab54-4186bc8484fe">5.3</a>)]</span><br>
</li>
</ul>
<p>Adverse reactions commonly reported by COC users are:</p>
<ul>
<li>Irregular <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1344897-63d9-4abb-a14c-3cffe4452a1f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The clinical trial that evaluated the safety and efficacy of LoSeasonique was a 12-month, multicenter, non-comparative open-label study, which enrolled women aged 18-41, of whom 2,185 took at least one dose of LoSeasonique. </p>
<p><span class="Bold">Adverse Reactions Leading to Study Discontinuation: </span>11% of the women discontinued from the clinical trial due to an adverse reaction; the most common adverse reactions leading to discontinuation were irregular and/or heavy <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p><span class="Bold">Common Treatment-Emergent Adverse Reactions (≥ 5% of women): </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (33%); irregular and/or heavy <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> (13%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (11%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (11%), <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (8%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_7311004a-7f40-41e6-8d38-b6ab6a1e686a"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No formal drug-drug interaction studies were conducted with LoSeasonique.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d75a1d6e-a4f5-4701-b255-9dfbd80dcf9d"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Changes in Contraceptive Effectiveness Associated with Co-Administration of Other Products</h2>
<p class="First">If a woman on hormonal contraceptives takes a drug or herbal product that induces enzymes, including CYP3A4, that metabolize contraceptive hormones, counsel her to use additional contraception or a different method of contraception. Drugs or herbal products that induce such enzymes may decrease the plasma concentrations of contraceptive hormones, and may decrease the effectiveness of hormonal contraceptives or increase breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include:</p>
<ul>
<li>barbiturates</li>
<li>bosentan</li>
<li>carbamazepine</li>
<li>felbamate</li>
<li>griseofulvin</li>
<li>oxcarbazepine</li>
<li>phenytoin</li>
<li>rifampin </li>
<li>St. John’s wort</li>
<li>topiramate</li>
</ul>
<p><span class="Underline">HIV protease inhibitors</span>: Significant changes (increase or decrease) in the plasma levels of the estrogen and progestin have been noted in some cases of co-administration of HIV protease inhibitors.</p>
<p><span class="Underline">Antibiotics</span>: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.</p>
<p>Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca4f1460-6787-4cb6-b70c-cdc1987b96bc"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Increase in Plasma Levels of Estradiol Associated with Co-Administered Drugs</h2>
<p class="First">Co-administration of atorvastatin and certain COCs containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_819270fc-1f83-406e-81e6-06634107ff38"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Changes in Plasma Levels of Co-Administered Drugs</h2>
<p class="First">Combination OCs containing some synthetic estrogens (e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. Combination OCs have been shown to significantly decrease plasma concentrations of lamotrigine likely due to induction of lamotrigine glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments of lamotrigine may be necessary. Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_4e3152b4-57b9-445a-ada3-dc7b7a5459e7"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_c7a03da7-e378-4d3f-bfdd-c096068f973d"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">There is little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (including cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span>) following exposure to low dose COCs prior to conception or during early pregnancy.</p>
<p>The administration of COCs to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy. Combination OCs should not be used during pregnancy to treat threatened or habitual abortion.</p>
<p>Women who do not breastfeed may start COCs no earlier than four to six weeks postpartum.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_620bb399-fd38-4639-a372-eb22e95c21cc"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. Estrogen-containing OCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well established; however, it can occur at any time in some women. Small amounts of estrogen and progestin from low dose COCs are present in breast milk, but these doses have not produced adverse effects in breastfeeding infants.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_d6a664e2-de38-4e64-a030-4d5ff332439b"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of LoSeasonique have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 18 as for users 18 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_97422541-46d9-4831-b1d4-937490f57111"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">This product has not been studied in postmenopausal women and is not indicated in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d8066d68-c85d-4e09-b76b-ec8fb8b80499"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There have been no reports of serious ill effects from <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including ingestion by children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_308c90dd-cf9b-491f-9992-55119765f63e"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LoSeasonique (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets provide an oral contraceptive regimen of 84 orange tablets each containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, followed by 7 yellow tablets each containing 0.01 mg ethinyl estradiol.</p>
<p>The structural formulas for the active components are:</p>
<div class="Figure">
<img alt="Structural formula of levonorgestrel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-02.jpg"><p class="MultiMediaCaption">Levonorgestrel C<span class="Sub">21</span>H<span class="Sub">28</span>O<span class="Sub">2 </span>MW: 312.4</p>
</div>
<p>Levonorgestrel is chemically 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-, (-)-.</p>
<div class="Figure">
<img alt="Structural formula of ethinyl estradiol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-03.jpg"><p class="MultiMediaCaption">Ethinyl Estradiol C<span class="Sub">20</span>H<span class="Sub">24</span>O<span class="Sub">2 </span>MW: 296.4</p>
</div>
<p>Ethinyl Estradiol is 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-.</p>
<p><span class="Italics">Inactive ingredients</span> for the orange tablets include FD&amp;C Yellow # 6 (Sunset Yellow) aluminum lake, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, corn starch, titanium dioxide and triacetin.</p>
<p><span class="Italics">Inactive ingredients</span> for the yellow tablets include anhydrous lactose, FD&amp;C Yellow # 10 aluminum lake, FD&amp;C Yellow # 6 (Sunset Yellow) aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polacrilin potassium, polyethylene glycol, polysorbate 80 and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a00e3039-5681-4029-ac70-ae1b38477b55"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_bb200179-7e67-4cb2-b00e-c337bdfd490d"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Combination OCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_c21e5c45-0ce2-4fac-9928-a13e024e9e00"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>No specific investigation of the absolute bioavailability of LoSeasonique in humans has been conducted. However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability nearly 100%) and is not subject to first-pass metabolism. Ethinyl estradiol is rapidly and almost completely absorbed from the gastrointestinal tract but, due to first-pass metabolism in gut mucosa and liver, the systemic bioavailability of ethinyl estradiol is approximately 43%.</p>
<p>The mean plasma pharmacokinetic parameters of LoSeasonique  following a single oral dose of three levonorgestrel/ethinyl estradiol combination tablets in normal healthy women under fasting conditions are reported in <a href="#id_89da7313-de15-41a6-ae28-aa37af210204">Table 3</a>.</p>
<a name="id_89da7313-de15-41a6-ae28-aa37af210204"></a><table border="single" width="407.000">
<caption><span>Table 3: Mean (SD) Pharmacokinetic Parameters Following a Single Dose Administration of Three Tablets of LoSeasonique in 30 Healthy Women under Fasting Conditions</span></caption>
<col width="23.1%">
<col width="20.9%">
<col width="18.7%">
<col width="18.7%">
<col width="18.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">AUC<span class="Sub">0-∞</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">T<span class="Sub">max</span></span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">T<span class="Sub">½</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Levonorgestrel</td>
<td class="Botrule Rrule" align="center" valign="top">76.5 ± 24.9 ng*hr/mL</td>
<td class="Botrule Rrule" align="center" valign="top">6.0 ± 1.6 ng/mL</td>
<td class="Botrule Rrule" align="center" valign="top">1.6 ± 0.6 hours</td>
<td class="Botrule" align="center" valign="top">28.5 ± 8.7 hours</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Ethinyl estradiol</td>
<td class="Rrule" align="center" valign="top">1335.8 ± 365.3 pg*hr/mL</td>
<td class="Rrule" align="center" valign="top">122.8 ± 39.5 pg/mL</td>
<td class="Rrule" align="center" valign="top">1.8 ± 0.7 hours</td>
<td class="Botrule" align="center" valign="top">17.5 ± 7.4 hours</td>
</tr>
</tbody>
</table>
<p>AUC<span class="Sub">0-∞ </span>= area under the drug concentration curve from time 0 to infinity</p>
<p>C<span class="Sub">max</span> = maximum concentration</p>
<p>T<span class="Sub">max</span> = time to maximum concentration</p>
<p>The effect of food on the rate and the extent of levonorgestrel and ethinyl estradiol absorption following oral administration of LoSeasonique has not been evaluated.</p>
<p><span class="Italics">Distribution</span></p>
<p>The apparent volume of distribution of levonorgestrel and ethinyl estradiol is reported to be approximately 1.8 L/kg and 4.3 L/kg, respectively. Levonorgestrel is about 97.5 to 99% protein-bound, principally to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and, to a lesser extent, serum albumin. Ethinyl estradiol is about 95 to 97% bound to serum albumin. Ethinyl estradiol does not bind to SHBG, but induces SHBG synthesis, which leads to decreased levonorgestrel clearance. Following repeated daily dosing of combination levonorgestrel/ethinyl estradiol OCs, levonorgestrel plasma concentrations accumulate more than predicted based on single-dose pharmacokinetics, due in part, to increased SHBG levels that are induced by ethinyl estradiol, and a possible reduction in hepatic metabolic capacity.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.</p>
<p>First-pass metabolism of ethinyl estradiol involves formation of ethinyl estradiol-3-sulfate in the gut wall, followed by 2-hydroxylation of a portion of the remaining untransformed ethinyl estradiol by hepatic cytochrome P-450 3A4 (CYP3A4). Levels of CYP3A4 vary widely among individuals and can explain the variation in rates of ethinyl estradiol hydroxylation. Hydroxylation at the 4-, 6-, and 16- positions may also occur, although to a much lesser extent than 2-hydroxylation. The various hydroxylated metabolites are subject to further methylation and/or conjugation.</p>
<p><span class="Italics">Excretion</span></p>
<p>About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates. Ethinyl estradiol is excreted in the urine and feces as glucuronide and sulfate conjugates, and then undergoes enterohepatic recirculation.</p>
<p><span class="Italics">Race</span></p>
<p>The effect of race on the pharmacokinetics of LoSeasonique has not been evaluated. </p>
<p><span class="Italics">Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>No formal studies were conducted to evaluate the effect of hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of LoSeasonique. However, steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_6908f5db-acbb-4e60-bb2d-dd331f7c3671"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_3d6646f6-1155-4c86-9731-85aadca5bb24"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">[See<span class="Italics"> WARNINGS AND PRECAUTIONS (<a href="#i4i_section_id_0c6401f3-e220-49dd-9c5a-b0261311ed05">5.2</a>, <a href="#i4i_section_id_34c1c3b7-9730-42e0-ab54-4186bc8484fe">5.3</a>)</span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_72cebd2b-7548-4001-858e-cdf970c69126"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a 12-month multicenter open-label clinical trial, 2,185 women aged 18-41 were studied to assess the safety and efficacy of LoSeasonique, completing the equivalent of 20,937 28-day cycles of exposure. The racial demographic of those enrolled was: Caucasian (75%), African-American (12%), Hispanic (10%), Asian (2%), and Other (2%). There were no exclusions for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) or weight. The weight range for those women treated was 87 to 381 lbs., with a mean weight of 159 lbs. Among the women in the trial, 59% were current or recent hormonal contraceptive users, 30% were prior users (had used hormonal contraceptives in the past but not in the 6 months prior to enrollment) and 11% were new starts. Of treated women, 14.2% were lost to follow-up, 11.6% discontinued due to an adverse event, and 10.3% discontinued by withdrawing their consent. </p>
<p>The pregnancy rate (Pearl Index [PI]) in women aged 18 to 35 years was 2.74 pregnancies per 100 women-years of use (95% confidence interval 1.92 – 3.78), based on 36 pregnancies that occurred after the onset of treatment and within 14 days after the last combination pill. Cycles in which conception did not occur, but which included the use of backup contraception, were not included in the calculation of the PI. The PI includes patients who did not take the drug correctly.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5ff9176f-54e4-47a5-a43d-4c326272a7c0"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Lo Seasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) are available in an Extended-Cycle Tablet Dispenser that contains 84 round, orange tablets and 7 round, yellow tablets. Each orange tablet (debossed stylized <span class="Bold">b</span> on one side and <span class="Bold">28 </span>on the other side) contains 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol. Each yellow tablet (debossed stylized <span class="Bold">b</span> on one side and <span class="Bold">556 </span>on the other side) contains 0.01 mg ethinyl estradiol. The tablets should not be removed from the protective <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging and outer plastic dispenser to avoid damage to the product. The plastic dispenser should be kept in the foil pouch until dispensed to the patient.</p>
<p>Box of 2 Extended-Cycle Tablet Dispensers NDC 51285-092-87</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20 to 25°C (68 to77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_440c405a-1531-494b-9f96-3ed37a98f42a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-APPROVED PATIENT LABELING (<a href="#i4i_section_id_5220d496-3129-43f4-b60e-8df191fd6004">17.2</a>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7018f9a-7ac8-4cb4-b949-c638fe514a5d"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<ul>
<li>Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs.</li>
<li>Counsel patients that this product does not protect against HIV-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</li>
<li>Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed.</li>
<li>Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs.</li>
<li>Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. This is less likely to occur if breastfeeding is well established.</li>
<li>Counsel any patient who starts COCs postpartum, and who has not yet had a period, to use an additional method of contraception until she has taken an orange tablet for 7 consecutive days.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5220d496-3129-43f4-b60e-8df191fd6004"></a><a name="section-15.2"></a><p></p>
<h2>17.2 FDA Approved Patient Labeling</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_80dcb75e-1e05-46a1-a03f-566007e802ed"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Guide for Using LoSeasonique</span></p>
<div class="Warning">
<a name="id_1a6bdcaa-862b-4116-ab65-5bffcaabd1ed"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">WARNING TO WOMEN WHO SMOKE</span></p>
<p>Do not use LoSeasonique if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects from birth control pills, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, blood clots or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. This risk increases with age and the number of cigarettes you smoke.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_0f0cfd46-7c23-40e3-ab04-c53dadf71cad"></a><a name="section-16.1"></a><p></p>
<p class="First">Birth control pills help to lower the chances of becoming pregnant. They do not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</p>
<p><span class="Bold">WHAT IS LoSeasonique?</span></p>
<p>LoSeasonique is a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called levonorgestrel.</p>
<p><span class="Bold">HOW WELL DOES LoSeasonique WORK?</span></p>
<p>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The more carefully you follow the directions, the less chance you have of getting pregnant.</p>
<p>Based on the results of a single clinical study lasting 12 months, 2 to 4 women, out of 100 women, may get pregnant during the first year they use LoSeasonique.</p>
<p>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</p>
<a name="id_e5671bf5-94d0-4643-9786-08074cac88fe"></a><table border="triple" width="456.000">
<col width="29.8%">
<col width="22.4%">
<col width="43.4%">
<col width="4.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">Fewer than 1 pregnancy per 100 women in one year</td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Fewer Pregnancies</span></p></td>
<td class="Botrule Rrule" align="left" valign="top"><ul>
<li>Implants</li>
<li>Injections</li>
<li>Intrauterine devices</li>
<li>Sterilization</li>
</ul></td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" rowspan="8" valign="top"><p class="First"><img alt="Arrow" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-04.jpg"></p></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"><ul>
<li><span class="Bold">Birth control pills</span></li>
<li>Skin patch </li>
<li>Vaginal ring with hormones</li>
</ul></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">10-20 pregnancies<br> per 100 women <br>in one year </td>
<td class="Botrule Rrule" align="left" valign="top"><ul>
<li>Condoms </li>
<li>Diaphragm</li>
</ul></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><ul>
<li>No sex during the most fertile days of the monthly cycle</li>
<li><span class="Underline">Spermicide</span></li>
<li>Withdrawal </li>
</ul></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">85 or more pregnancies per 100 women in one year</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">More Pregnancies</span></p></td>
<td class="Botrule Rrule" align="left" valign="top"><ul><li>No birth control</li></ul></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">HOW DO I TAKE LoSeasonique?</span></p>
<ol>
<li>Take one pill every day at the same time. If you miss pills you could get pregnant. This includes starting the pack late. The more pills you miss, the more likely you are to get pregnant.</li>
<li>Many women have spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or may feel sick to their stomach during the first few months of taking LoSeasonique. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your healthcare provider.</li>
<li>Missing pills can also cause spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</li>
<li>If you have trouble remembering to take LoSeasonique, talk to your healthcare provider about how to make pill-taking easier or about using another method of birth control.</li>
</ol>
<p><span class="Bold"><span class="Underline">Before </span> you start taking LoSeasonique</span></p>
<ol>
<li>Decide what time of day you want to take your pill. It is important to take it at about the same time every day.</li>
<li>Look at your Extended-Cycle Tablet Dispenser. Your Tablet Dispenser consists of 3 trays with cards that hold 91 individually sealed pills (a 13-week or 91-day cycle). The 91 pills consist of 84 orange and 7 yellow pills. Trays 1 and 2 each contain 28 orange pills (4 rows of 7 pills). Tray 3 contains 35 pills consisting of 28 orange pills (4 rows of 7 pills) and 7 yellow pills (1 row of 7 pills). <div class="Figure"><img alt="LoSeasonique <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-05.jpg"></div> </li>
<li>Also find:<ul>
<li>Where on the first tray in the pack to start taking pills (upper left corner at the start arrow) and</li>
<li>In what order to take the pills (follow the weeks and arrow).</li>
</ul>
</li>
<li>Be sure you have ready at all times another kind of birth control (such as condoms or spermicides), to use as a back-up in case you miss pills.</li>
</ol>
<p><span class="Bold">When to Start LoSeasonique</span></p>
<ol>
<li>Take the first orange pill on the Sunday after your period starts, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the first orange pill that same day.</li>
<li>Use another method of birth control (such as condoms or spermicides) as a back-up method if you have sex anytime from the Sunday you start your first orange pill until the next Sunday (first 7 days). If you have been using a different hormonal method of birth control (such as a different pill, the “patch,? or the “vaginal ring?), you need to use another method of birth control (such as condoms or spermicides) each time you have sex after stopping your old method of birth control until you have taken LoSeasonique for 7 days.</li>
</ol>
<p><span class="Bold">How to Take LoSeasonique</span></p>
<ol>
<li>Take one pill at the same time every day until you have taken the last pill in the tablet dispenser.<ul>
<li>Do not skip pills even if you are experiencing spotting or bleeding  or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</li>
<li>Do not skip pills even if you do not have sex very often.<br>
</li>
</ul>
</li>
<li>When you finish a tablet dispenser<p class="First"></p>
<ul><li>After taking the last yellow pill, start taking the first orange pill from a new Extended-Cycle Tablet Dispenser the very next day (this should be on a Sunday) regardless of when your period started.<br>
</li></ul>
</li>
<li>If you miss your scheduled period when you are taking the yellow pills, contact your healthcare provider because you may be pregnant. If you are pregnant, you should stop taking LoSeasonique.</li>
</ol>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1 </span>orange pill:</p>
<ol>
<li>Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</li>
<li>You do not need to use a back-up birth control method if you have sex.</li>
</ol>
<p>If you <span class="Bold">MISS 2</span> orange pills in a row: </p>
<ol>
<li>Take 2 pills on the day you remember, and 2 pills the next day.</li>
<li>Then take 1 pill a day until you finish the pack.</li>
<li>You could become pregnant if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss two pills. You MUST use another birth control method (such as condoms or spermicide) as a back up for the 7 days after you restart your pills.</li>
</ol>
<p>If you <span class="Bold">MISS 3 OR MORE</span> orange pills in a row:</p>
<ol>
<li>Do not take the missed pills. Keep taking 1 pill every day as indicated on the pack until you have completed all of the remaining pills in the pack. For example: If you resume taking the pill on Thursday, take the pill under “Thursday? and do not take the missed pills. You may experience <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the week following the missed pills.</li>
<li>You could become pregnant if you have sex during the days of missed pills or during the first <span class="Bold"><span class="Underline">7 days</span></span> after restarting your pills.</li>
<li>You MUST use a non-hormonal birth control method (such as condoms or spermicide) as a back-up when you miss pills and for the first 7 days after you restart your pills. If you do not have your period when you are taking the yellow pills, call your healthcare provider because you may be pregnant.</li>
</ol>
<p>If you <span class="Bold">MISS ANY</span> of the 7 yellow pills:</p>
<ol>
<li>Throw away the missed pills.</li>
<li>Keep taking the scheduled pills until the pack is finished.</li>
<li>You do not need a back-up method of birth control.</li>
</ol>
<p><span class="Bold">Finally, if you are still not sure what to do about the pills you have missed</span></p>
<ol>
<li>Use a back-up method anytime you have sex.</li>
<li>Keep taking one pill each day until you contact your healthcare provider.</li>
</ol>
<p><span class="Bold">WHO SHOULD NOT TAKE LoSeasonique?</span></p>
<p>Your healthcare provider will not give you LoSeasonique if you have:</p>
<ul>
<li>Ever had breast cancer or any cancer that is sensitive to female hormones</li>
<li>Liver disease, including <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></li>
<li>Ever had blood clots in your arms, legs, or lungs</li>
<li>Ever had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>Ever had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart</li>
<li>An inherited problem with your blood that makes it clot more than normal</li>
<li>High blood pressure that medicine can't control</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> with kidney, eye, or blood vessel damage</li>
<li>Certain kinds of severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or changes in vision</li>
</ul>
<p>Also, do not take birth control pills if you:</p>
<ul>
<li>Smoke and are over 35 years old</li>
<li>Are pregnant</li>
</ul>
<p>Birth control pills may not be a good choice for you if you have ever had <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (yellowing of the skin or eyes) caused by pregnancy.</p>
<p><span class="Bold">WHAT ELSE SHOULD I KNOW ABOUT TAKING LoSeasonique?</span></p>
<p>Birth control pills do <span class="Bold"><span class="Italics"><span class="Underline">not</span></span></span> protect you against any <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span>, including HIV, the virus that causes AIDS.</p>
<p>Do not skip any pills, even if you do not have sex often.</p>
<p>Birth control pills should not be taken during pregnancy. However, birth control pills taken by <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> during pregnancy are not known to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like LoSeasonique, may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk, but this has not caused harmful effects in breastfeeding infants.</p>
<p>Tell your health care provider about all medicines and herbal products that you take. Some medicines and herbal products may make birth control pills less effective, including:</p>
<ul>
<li>barbiturates</li>
<li>bosentan</li>
<li>carbamazepine</li>
<li>felbamate</li>
<li>griseofulvin</li>
<li>oxcarbazepine</li>
<li>phenytoin</li>
<li>rifampin </li>
<li>St. John’s wort</li>
<li>topiramate</li>
</ul>
<p>Consider using another birth control method when you take medicines that may make birth control pills less effective.</p>
<p>Birth control pills may interact with lamotrigine, an anticonvulsant used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. This may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, so your physician may need to adjust the dose of lamotrigine.</p>
<p>If you have <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, your birth control pills may not work as well. Use another birth control method, like condoms or a spermicide, until you check with your health care provider.</p>
<p><span class="Bold">WHAT ARE THE MOST SERIOUS RISKS OF TAKING BIRTH CONTROL PILLS?</span></p>
<p>Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, or age &gt; 35. It is possible to die from a problem caused by a blood clot, such as a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Some examples of serious blood clots are blood clots in the:</p>
<ul>
<li>Legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>)</li>
<li>Lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>)</li>
<li>Eyes (loss of eyesight)</li>
<li>Heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>)</li>
<li>Brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>)</li>
</ul>
<p>A few women who take birth control pills may get:</p>
<ul>
<li>High blood pressure</li>
<li>Gallbladder problems</li>
<li>Rare cancerous or noncancerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></li>
</ul>
<p>All of these events are uncommon in healthy women.</p>
<p><span class="Bold">Call your health care provider right away if you have:</span></p>
<ul>
<li>Persistent <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span> </li>
<li>Sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> </li>
<li>Sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, partial or complete </li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your chest</li>
<li>Sudden, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> unlike your usual <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg, or trouble speaking</li>
<li>Yellowing of the skin or eyeballs</li>
</ul>
<p><span class="Bold">WHAT ARE COMMON SIDE EFFECTS OF BIRTH CONTROL PILLS?</span></p>
<p>The most common side effects of birth control pills are:</p>
<ul>
<li>Spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between menstrual periods</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
</ul>
<p>These side effects are usually mild and usually disappear with time.</p>
<p>Less common side effects are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></li>
<li>Less sexual desire</li>
<li><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">Blotchy</span> darkening of the skin, especially on the face</li>
<li>High blood sugar, especially in women who already have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>High fat levels in the blood.</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, especially if you have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in the past. Call your health care provider immediately if you have any thoughts of harming yourself.</li>
<li>Problems tolerating contact lenses</li>
<li>Weight changes</li>
</ul>
<p>This is not a complete list of possible side effects. Talk to your health care provider if you develop any side effects that concern you.</p>
<p>No serious problems have been reported from a birth control pill <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, even when accidentally taken by children.</p>
<p><span class="Bold">DO BIRTH CONTROL PILLS CAUSE CANCER?</span></p>
<p>Birth control pills do <span class="Underline">not</span> appear to cause breast cancer. However, if you have breast cancer now, or have had it in the past, do not use birth control pills because some breast cancers are sensitive to hormones.</p>
<p>Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</p>
<p><span class="Bold">WHAT SHOULD I KNOW ABOUT MY PERIOD WHEN TAKING LoSeasonique?</span></p>
<p>When you take LoSeasonique, which has a 91-day extended dosing cycle, you should expect to have 4 scheduled periods per year (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when you are taking the 7 yellow pills). Each period is likely to last about 2 to 3 days. However, you will probably have more <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting between your scheduled periods than if you were using a birth control pill with a 28-day dosing cycle. This <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting tends to decrease with time. Do not stop taking LoSeasonique because of this <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting. If the spotting continues for more than 7 consecutive days or if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is heavy, call your healthcare provider.</p>
<p><span class="Bold">WHAT IF I MISS MY SCHEDULED PERIOD WHEN TAKING LoSeasonique?</span></p>
<p>You should consider the possibility that you are pregnant if you miss your scheduled period (no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on the days that you are taking yellow tablets). Since scheduled periods are less frequent when you are taking LoSeasonique, notify your healthcare provider that you have missed your period and that you are taking LoSeasonique. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>. It is important that your healthcare provider evaluates you to determine if you are pregnant. Stop taking LoSeasonique if it is determined that you are pregnant.</p>
<p><span class="Bold">WHAT IF I WANT TO BECOME PREGNANT?</span></p>
<p>You may stop taking the pill whenever you wish. Consider a visit with your health care provider for a pre-pregnancy checkup before you stop taking the pill.</p>
<p>Rx only</p>
<p><span class="Bold">TEVA WOMEN’S HEALTH, INC.</span><br><span class="Bold">Subsidiary of TEVA PHARMACEUTICALS USA, INC.</span><br>Sellersville, PA  18960 </p>
<p>Iss. 6/2011</p>
<p>799-33-100090</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2997b979-e8e7-4cff-b6a2-cf6bfcb62991"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="LoSeasonique carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b8b5145-77ad-4817-8f9e-77fd7938242e&amp;name=f8fe52e5-fb64-4af2-9939-e1c623e875af-06.jpg"></div>
<p class="First">LoSEASONIQUE</p>
<p>levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg tablets</p>
<p>ethinyl estradiol 0.01 mg tablets</p>
<p>Rx only</p>
<p><span class="Bold">Usual Dosage:</span> One tablet daily for 91 consecutive days in the following order: 84 orange tablets followed by 7 yellow tablets as prescribed.</p>
<p>See enclosed package brochure.</p>
<p><span class="Bold">Pharmacist:</span> Dispense patient information with each prescription.</p>
<p>Contains 2 Extended-Cycle Tablet Dispensers, each containing 91 tablets: 84 orange tablets, each containing 0.1 mg levonorgestrel with 0.02 mg ethinyl estradiol, and 7 yellow tablets, each containing 0.01 mg ethinyl estradiol.</p>
<p>THIS PRODUCT (LIKE ALL ORAL CONTRACEPTIVES) IS INTENDED TO PREVENT PREGNANCY. IT DOES NOT PROTECT AGAINST <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV INFECTION</span> (AIDS) AND OTHER <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">SEXUALLY TRANSMITTED DISEASES</span>.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOSEASONIQUE 		
					</strong><br><span class="contentTableReg">levonorgestrel/ethinyl estradiol and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-092</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-092-87</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">84 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>LOSEASONIQUE 		
					</strong><br><span class="contentTableReg">levonorgestrel/ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVONORGESTREL</strong> (LEVONORGESTREL) </td>
<td class="formItem">LEVONORGESTREL</td>
<td class="formItem">0.1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.02 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;28</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022262</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>LOSEASONIQUE 		
					</strong><br><span class="contentTableReg">ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.01 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">B;556</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022262</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022262</td>
<td class="formItem">10/24/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Women's Health, Inc.
							(017038951)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f8fe52e5-fb64-4af2-9939-e1c623e875af</div>
<div>Set id: 2b8b5145-77ad-4817-8f9e-77fd7938242e</div>
<div>Version: 5</div>
<div>Effective Time: 20130604</div>
</div>
</div> <div class="DistributorName">Teva Women's Health, Inc.</div></p>
</body></html>
